A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer

Treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer with dual anti-HER2 therapy has been shown to improve outcomes. In the present pilot phase II study, patients with early-stage HER2-positive breast cancer received adjuvant treatment with dose-dense paclitaxel, trast...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Breast Cancer
Главные авторы: Iyengar, Neil M., Fornier, Monica N., Sugarman, Steven M., Theodoulou, Maria, Troso-Sandoval, Tiffany A., D’Andrea, Gabriella M., Drullinsky, Pamela R., Gajria, Devika, Goldfarb, Shari B., Comen, Elizabeth A., Lake, Diana E., Modi, Shanu, Traina, Tiffany A., Lacouture, Mario E., Chen, Melanie F., Patil, Sujata, Baselga, José, Norton, Larry, Hudis, Clifford A., Dang, Chau T.
Формат: Artigo
Язык:Inglês
Опубликовано: 2015
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4968930/
https://ncbi.nlm.nih.gov/pubmed/26454612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2015.09.009
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы